Henry Schein Closes Acquisition of Acentus

Henry Schein has completed its acquisition of Acentus, a medical supplier specializing in delivery of continuous glucose monitors (CGMs).

The transaction agreement was first revealed on November 20, 2024.

Tampa, Fla.-based Acentus has an annual revenue of about $35 million. Henry Schein said it expects the deal to be neutral to 2025 non-GAAP earnings per share (EPS) and accretive thereafter. Further financial terms were not disclosed.

This acquisition follows the company’s buy of Prism Medical Products in 2021 and Shield Health and Mini Pharmacy in 2023, reinforcing its homecare medical supplies portfolio. The company said its homecare medical products platform will now have annual revenue in excess of $350 million.

Acentus Founders Brett Carroll, Todd Cianfrocca, Greg Duvall, and Julio Valdivia will join Henry Schein.

“Henry Schein continues to expand upon our national homecare solutions platform to effectively address the evolving needs of our customers, which includes clinics, physician practices, health systems, and patients receiving care at home,” said Stanley M. Bergman, Chairman of the Board and CEO, Henry Schein. “The acquisition of Acentus represents an important step towards strengthening our position within the home medical supply market. By directly delivering CGM products to patients’ homes, we are enhancing our ability to serve our valued customers and drive growth.”